Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 61Recurrence 10Lymphoma 5Waldenstrom Macroglobulinemia 4Neoplasms, Plasma Cell 4Small Cell Lung Carcinoma 3Ovarian Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Kidney Neoplasms 2Hodgkin Disease 2Hematologic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Sezary Syndrome 1Salivary Gland Adenoma, Pleomorphic 1Renal Insufficiency 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1Neoplasm Metastasis 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Plasma Cell 1Leukemia 1Kidney Failure, Chronic 1

Interventions

Dexamethasone 4pomalidomide 2dexamethasone acetate 2dexamethasone 21-phosphate 2daratumumab 2auricularum 2Calcium Dobesilate 2Bortezomib 2navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1ixazomib 1carfilzomib 1Specimen Handling 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Melphalan 1Lenalidomide 1Gemcitabine 1Busulfan 1Biopsy 12-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Plasmacytoma × carfilzomib × Clear all
NCT03031730 2026-02-10

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Terminated
35 enrolled 10 charts
Plasma cell

Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡